Hepcvir(Sofosbuvir 400mg) is a prescription medicine used with other antiviral medicines to treat adults with chronic hepatitis C (Hep C) with or without cirrhosis (compensated). Hepcvir recommended with some combination of ribavirin, peginterferon-alfa, simeprevir, ledipasvir, daclatasvir, or velpatasvir to cure genotype 1 to 6 infections. Cure rates are 30 to 97% depending on the type of hepatitis C virus involved.
Hepcvir is safe and effective in patient who have had a liver transplant.Hepcvir (Sofosbuvir 400mg) is activated in the liver to the triphosphate GS-461203 by hydrolysis of the carboxylate ester by either of the enzymes cathepsin A or carboxylesterase 1, followed by cleaving of the phosphoramidate by the enzyme histidine triad nucleotide-binding protein 1 (HINT1), and subsequent repeated phosphorylation. Dephosphorylation creates the inactive metabolite GS-331077. The half life of Hepcvir is 0.4 hours, and the half life of GS-331007 is 27 hours. Following a single 400 mg oral dose of Hepcvir , 80% is excreted in urine, 14% in feces, and 2.5% in expired air recovery. However, of the urine recovery 78% was the metabolite (GS-331007) and 3.5% was Hepcvir (Sofosbuvir 400mg) has a number of ideal properties, once daily dosing, no meal restrictions, few adverse effects, minimal drug-drug interactions, high genetic barrier to resistance, good safety and efficacy in patients with advanced liver disease, and excellent sustained virologic response rates in patients with unfavorable baseline characteristics Hepcvir (Sofosbuvir 400mg) (in combination with ledipasvir, daclatasvir or simeprevir) should not be used with amiodarone due to the risk of abnormally slow heartbeats. Hepcvir (Sofosbuvir 400mg) is a substrate of P-glycoprotein, a transporter protein that pumps drugs and other substances from intestinal epithelium cells back into the gut.
Hepcvir may reactivate hepatitis B in those who have been previously infected. In combination with ledipasvir, daclatasvir or simeprevir it is not recommended with amiodarone due to the risk of an abnormally slow heartbeat. Hepcvir (Sofosbuvir 400mg ) alone has been assigned a Pregnancy Category B by the FDA (meaning that it there are no adequate and well-controlled studies in pregnant women but animal reproduction studies have not demonstrated a risk to the fetus and, or that adverse effects have been seen in animal studies, but adequate and well-controlled studies in pregnant women have not, in any trimester).
Active Ingeridents: Sofosbuvir-400MG
Company Name: Cipla
Package: 28 tabs/bottle
Strength : 400Mg
Sofosbuvir Mechanism of action:
Sofosbuvir is a prodrug using the ProTide biotechnology strategy. It is metabolized to the active antiviral agent 2'-deoxy-2'-α-fluoro-β-C-methyluridine-5'-triphosphate. The triphosphate serves as a faulty substrate for the NS5B protein, which is the viral RNA polymerase, accordingly goes about as an inhibitor of viral RNA combination.In spite of the fact that sofosbuvir has a 3’ hydroxyl gathering to go about as a nucleophile for an approaching NTP, a comparative nucleotide simple, 2’- deoxy-2’- α-fluoro-β-C-methylcytidine, is proposed to go about as a chain eliminator on the grounds e causes a steric clash with an incoming NTP. Sobosbuvir would act in a similar way. Before the disclosure of sofosbuvir, an assortment of nucleoside analogs had been analyzed as antihepatitis C medicines, yet these showed moderately low power. This low intensity emerges to a limited extent in light of the fact that the enzymatic expansion of the first of the three phosphate gatherings of the triphosphate is moderate. The plan of sofosbuvir, in light of the protide approach, stays away from this moderate stride by building the main phosphate aggregate into the structure of the medication amid union. Extra gatherings are appended to the phosphorus to briefly veil the two negative charges of the phosphate assemble, accordingly encouraging passage of the medication into the contaminated cell. The NS5B protein is a RNA-subordinate RNA polymerase basic for the viral multiplication cycle. Sofosbuvir and other nucleotide inhibitors of the HCV RNA polymerase exhibit a very high barrier to resistance development. This is an important advantage relative to HCV drugs that target other viral enzymes such as the protease, for which rapid resistance development has proved to be an important cause of therapeutic failure.
The recommended daily dose of Hepcvir(Sofosbuvir) is 400mg tablet to be taken once daily with or without food. Hepcvir (Sofosbuvir)should be used in combination with Ribavirin or in combination with Pegylated Interferon and Ribavirin for the treatment of CHC (Chronic Hepatitis C) in adults. It is highly advisable to administer the drug under strict medical supervision and advice.
Store at 25°C in a dry place.
Sofosbuvir Side effects:
The following serious adverse reactions are described below and elsewhere in the labeling:
Serious Symptomatic Bradycardia When Coadministered with Amiodarone and Another HCV Direct Acting Antiviral [see WARNINGS AND PRECAUTIONS].
Clinical Trials Experience
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
When Hepcvir is administered with ribavirin or peginterferon alfa/ribavirin, refer to the respective prescribing information for a description of adverse reactions associated with their use.
Safety and efficacy have not been established in patients younger than 18 years. Consult WARNINGS section for additional precautions.
Hepcvir (Sofosbuvir) is a prescription drug and should be used under proper medical guidance and advice. The information provided here is for general educational purposes only and does not constitute medical or pharmaceutical advice which should be sought from qualified medical and pharmaceutical advisers.